{"id": "article-38808_0", "title": "Mirabegron -- Continuing Education Activity", "content": "Mirabegron is a medication used in the management of overactive bladder. It is in the sympathomimetic class of medications. It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. This activity reviews the indications, action, and contraindications for mirabegron as a valuable agent in the management of overactive bladder, including the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with overactive bladder and related conditions.", "contents": "Mirabegron -- Continuing Education Activity. Mirabegron is a medication used in the management of overactive bladder. It is in the sympathomimetic class of medications. It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. This activity reviews the indications, action, and contraindications for mirabegron as a valuable agent in the management of overactive bladder, including the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with overactive bladder and related conditions."}
{"id": "article-38808_1", "title": "Mirabegron -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of mirabegron. Review the indications for initiating therapy with mirabegron. Outline the possible adverse effects associated with mirabegron. Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from mirabegron therapy. Access free multiple choice questions on this topic.", "contents": "Mirabegron -- Continuing Education Activity. Objectives: Identify the mechanism of action of mirabegron. Review the indications for initiating therapy with mirabegron. Outline the possible adverse effects associated with mirabegron. Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from mirabegron therapy. Access free multiple choice questions on this topic."}
{"id": "article-38808_2", "title": "Mirabegron -- Indications", "content": "The International Continence Society definition of overactive bladder (OAB) is \"urinary urgency, usually accompanied by frequency, nocturia, with or without urge urinary incontinence.\" [1] It is important to understand that OAB isn't an exact disease but a symptom complex with multiple and distinct etiologies. It is an incredibly embarrassing condition, and many patients are uncomfortable discussing it with their providers. The treatment of OAB includes a three-step algorithm: lifestyle modification, pharmacotherapy, and minimally invasive intervention. Lifestyle and behavioral modifications involve paying close attention to fluid consumption, bladder irritants, bladder training, and pelvic muscle floor therapy. The second line includes using anticholinergics or beta-3 adrenoceptor agonists. The third line consists of the injection of\u00a0intradetrusor onabotulinumtoxinA, sacral neuromodulation, and percutaneous posterior tibial nerve stimulation. As per\u00a0AUA/SUFU guidelines, in rare cases, fourth-Line Treatment options include augmentation cystoplasty and Urinary Diversion for severe refractor complicated OAB patients. [2]", "contents": "Mirabegron -- Indications. The International Continence Society definition of overactive bladder (OAB) is \"urinary urgency, usually accompanied by frequency, nocturia, with or without urge urinary incontinence.\" [1] It is important to understand that OAB isn't an exact disease but a symptom complex with multiple and distinct etiologies. It is an incredibly embarrassing condition, and many patients are uncomfortable discussing it with their providers. The treatment of OAB includes a three-step algorithm: lifestyle modification, pharmacotherapy, and minimally invasive intervention. Lifestyle and behavioral modifications involve paying close attention to fluid consumption, bladder irritants, bladder training, and pelvic muscle floor therapy. The second line includes using anticholinergics or beta-3 adrenoceptor agonists. The third line consists of the injection of\u00a0intradetrusor onabotulinumtoxinA, sacral neuromodulation, and percutaneous posterior tibial nerve stimulation. As per\u00a0AUA/SUFU guidelines, in rare cases, fourth-Line Treatment options include augmentation cystoplasty and Urinary Diversion for severe refractor complicated OAB patients. [2]"}
{"id": "article-38808_3", "title": "Mirabegron -- Indications", "content": "The medications typically used in OAB are in the antimuscarinic\u00a0class. However, their broad side-effect profile must be used cautiously, especially in patients with acute angle-closed glaucoma, older patients, and chronic constipation. Mirabegron, a beta-3 adrenoceptor agonist, has been shown to have high safety and efficacy profile by large random placebo-controlled clinical trials. Mirabegron is used to treat urgency, urge urinary incontinence, and increased urinary frequency found in the overactive bladder. [3] It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. [4] Mirabegron has been reported to have better tolerance and compliance by patients as compared to antimuscarinics. In this article, we will cover the use of mirabegron.", "contents": "Mirabegron -- Indications. The medications typically used in OAB are in the antimuscarinic\u00a0class. However, their broad side-effect profile must be used cautiously, especially in patients with acute angle-closed glaucoma, older patients, and chronic constipation. Mirabegron, a beta-3 adrenoceptor agonist, has been shown to have high safety and efficacy profile by large random placebo-controlled clinical trials. Mirabegron is used to treat urgency, urge urinary incontinence, and increased urinary frequency found in the overactive bladder. [3] It received approval from the US Food and Drug Administration (FDA) in June 2012 for treating overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. [4] Mirabegron has been reported to have better tolerance and compliance by patients as compared to antimuscarinics. In this article, we will cover the use of mirabegron."}
{"id": "article-38808_4", "title": "Mirabegron -- Mechanism of Action", "content": "The human bladder expresses various sympathetic and parasympathetic receptors to help regulate micturition. Activation of the parasympathetic system will result in bladder contraction. Receptors positively affecting bladder contraction and micturition include the M2 and M3 receptor subtypes, which function via the parasympathetic nervous system. [5] These receptors work to increase intracellular calcium and down-regulate cyclic-adenosine, respectively, which will increase muscle contraction. Negatively affecting micturition predominantly includes the sympathetic beta-3 adrenergic receptors. [6] Mirabegron is a beta-3 receptor agonist which will cause detrusor muscle relaxation. Animal studies have shown that beta-3 receptor agonists exhibit a dose-dependent detrusor relaxation (mediated via up-regulation of cyclic-adenosine) during the storage phase of micturition. [4] This way, mirabegron can aid in the symptomatic relief of OAB and\u00a0symptoms of urge urinary incontinence, urgency, and urinary frequency.", "contents": "Mirabegron -- Mechanism of Action. The human bladder expresses various sympathetic and parasympathetic receptors to help regulate micturition. Activation of the parasympathetic system will result in bladder contraction. Receptors positively affecting bladder contraction and micturition include the M2 and M3 receptor subtypes, which function via the parasympathetic nervous system. [5] These receptors work to increase intracellular calcium and down-regulate cyclic-adenosine, respectively, which will increase muscle contraction. Negatively affecting micturition predominantly includes the sympathetic beta-3 adrenergic receptors. [6] Mirabegron is a beta-3 receptor agonist which will cause detrusor muscle relaxation. Animal studies have shown that beta-3 receptor agonists exhibit a dose-dependent detrusor relaxation (mediated via up-regulation of cyclic-adenosine) during the storage phase of micturition. [4] This way, mirabegron can aid in the symptomatic relief of OAB and\u00a0symptoms of urge urinary incontinence, urgency, and urinary frequency."}
{"id": "article-38808_5", "title": "Mirabegron -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: According to the manufacturer's\u00a0product labeling, mirabegron reaches maximum plasma concentrations (Cmax) at approximately 3.5 hours. Steady-state concentrations are achieved within seven days. In adults, there are no clinically significant differences in mirabegron pharmacokinetics when administered with or without food. However, in pediatric patients, fasted Cmax and AUC increased by 170% and 80%, respectively, compared to the fed state following the administration of mirabegron Granules.", "contents": "Mirabegron -- Mechanism of Action -- Pharmacokinetics. Absorption: According to the manufacturer's\u00a0product labeling, mirabegron reaches maximum plasma concentrations (Cmax) at approximately 3.5 hours. Steady-state concentrations are achieved within seven days. In adults, there are no clinically significant differences in mirabegron pharmacokinetics when administered with or without food. However, in pediatric patients, fasted Cmax and AUC increased by 170% and 80%, respectively, compared to the fed state following the administration of mirabegron Granules."}
{"id": "article-38808_6", "title": "Mirabegron -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: Mirabegron has an extensive distribution with the volume of distribution at steady-state (Vss) 1670 L. Mirabegron is bound (approximately 71%) to human plasma proteins, including albumin and alpha-1 acid glycoprotein. Mirabegron distributes to erythrocytes. Mirabegron volume of distribution is relatively higher in pediatric patients and is proportional to body weight.", "contents": "Mirabegron -- Mechanism of Action -- Pharmacokinetics. Distribution: Mirabegron has an extensive distribution with the volume of distribution at steady-state (Vss) 1670 L. Mirabegron is bound (approximately 71%) to human plasma proteins, including albumin and alpha-1 acid glycoprotein. Mirabegron distributes to erythrocytes. Mirabegron volume of distribution is relatively higher in pediatric patients and is proportional to body weight."}
{"id": "article-38808_7", "title": "Mirabegron -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Mirabegron is metabolized in the liver via multiple pathways involving dealkylation, oxidation, glucuronidation, and hydrolysis. Metabolites are not pharmacologically active. Studies have also shown the involvement of butyrylcholinesterase, and UGT in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6. In poor metabolizers of CYP2D6, mean Cmax and AUC are approximately 16% and 17% higher than in extensive metabolizers of CYP2D6.", "contents": "Mirabegron -- Mechanism of Action -- Pharmacokinetics. Metabolism: Mirabegron is metabolized in the liver via multiple pathways involving dealkylation, oxidation, glucuronidation, and hydrolysis. Metabolites are not pharmacologically active. Studies have also shown the involvement of butyrylcholinesterase, and UGT in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6. In poor metabolizers of CYP2D6, mean Cmax and AUC are approximately 16% and 17% higher than in extensive metabolizers of CYP2D6."}
{"id": "article-38808_8", "title": "Mirabegron -- Mechanism of Action -- Pharmacokinetics", "content": "Excretion: The mean elimination half-life (t1/2) of mirabegron is approximately 50 hours in adult patients and 26 to 31 hours in pediatric patients(mirabegron granules). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Approximately\u00a0 55% is excreted in the urine, 34% in the feces, and ~25% in the urine(unchanged).", "contents": "Mirabegron -- Mechanism of Action -- Pharmacokinetics. Excretion: The mean elimination half-life (t1/2) of mirabegron is approximately 50 hours in adult patients and 26 to 31 hours in pediatric patients(mirabegron granules). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Approximately\u00a0 55% is excreted in the urine, 34% in the feces, and ~25% in the urine(unchanged)."}
{"id": "article-38808_9", "title": "Mirabegron -- Administration", "content": "Mirabegron is a once-daily orally administered drug. [4] It is available in 25 mg or 50 mg strengths. The lower-strength tablet is recommended as a starting dose for patients with severe renal or moderate hepatic impairment. The higher dose tablet is recommended for patients to take with or without food if they tolerate the lower dose. [4] Other therapeutic routes of administration (intravenous, rectal, enteral, epidural, intracerebral, etc.) for mirabegron are not FDA-approved in the treatment of OAB. Mirabegron may take 4 to 8 weeks before patients see improvements in their symptoms. [2] Mirabegron is available in extended-release tablets, extended-release granules, and as an oral suspension.", "contents": "Mirabegron -- Administration. Mirabegron is a once-daily orally administered drug. [4] It is available in 25 mg or 50 mg strengths. The lower-strength tablet is recommended as a starting dose for patients with severe renal or moderate hepatic impairment. The higher dose tablet is recommended for patients to take with or without food if they tolerate the lower dose. [4] Other therapeutic routes of administration (intravenous, rectal, enteral, epidural, intracerebral, etc.) for mirabegron are not FDA-approved in the treatment of OAB. Mirabegron may take 4 to 8 weeks before patients see improvements in their symptoms. [2] Mirabegron is available in extended-release tablets, extended-release granules, and as an oral suspension."}
{"id": "article-38808_10", "title": "Mirabegron -- Administration", "content": "In addition to monotherapy, combination therapy\u00a0with low dose mirabegron (25 mg) and a low dose of solifenacin (5 mg), an anti-muscarinic, has been shown to significantly improve urinary urgency and urgency incontinence when compared to monotherapy. Three large double-blind, randomized controlled trials (SYMPHONY, BESIDE, and SYNERGY) have shown the safety and efficacy of combination therapy. [7] [8] [9] Recently, the FDA has approved combination therapy for patients with urinary urgency. [8]", "contents": "Mirabegron -- Administration. In addition to monotherapy, combination therapy\u00a0with low dose mirabegron (25 mg) and a low dose of solifenacin (5 mg), an anti-muscarinic, has been shown to significantly improve urinary urgency and urgency incontinence when compared to monotherapy. Three large double-blind, randomized controlled trials (SYMPHONY, BESIDE, and SYNERGY) have shown the safety and efficacy of combination therapy. [7] [8] [9] Recently, the FDA has approved combination therapy for patients with urinary urgency. [8]"}
{"id": "article-38808_11", "title": "Mirabegron -- Administration -- Patients with Hepatic Impairment", "content": "For mild(Child-Pugh Class A\u00a0 starting dose is 25 mg, and the maximum dose is 50 mg. For moderate hepatic impairment(Child-Pugh Class B).\u00a0starting, and the maximum recommended dose is 25 mg. The use of mirabegron is not recommended for severe hepatic impairment (Child-Pugh Class C) [10]", "contents": "Mirabegron -- Administration -- Patients with Hepatic Impairment. For mild(Child-Pugh Class A\u00a0 starting dose is 25 mg, and the maximum dose is 50 mg. For moderate hepatic impairment(Child-Pugh Class B).\u00a0starting, and the maximum recommended dose is 25 mg. The use of mirabegron is not recommended for severe hepatic impairment (Child-Pugh Class C) [10]"}
{"id": "article-38808_12", "title": "Mirabegron -- Administration -- Patients with Renal Impairment", "content": "eGFR 30 to 89 mL/min/1.73 m^2 -\u00a0 maximum dose is\u00a0\u00a050 mg once daily eGFR 15 to 29 mL/min/1.73 m^2 -\u00a0 maximum dose is 25 mg once daily eGFR < 15 mL/min/1.73 m^2 or\u00a0patient requiring dialysis- Use is not recommended", "contents": "Mirabegron -- Administration -- Patients with Renal Impairment. eGFR 30 to 89 mL/min/1.73 m^2 -\u00a0 maximum dose is\u00a0\u00a050 mg once daily eGFR 15 to 29 mL/min/1.73 m^2 -\u00a0 maximum dose is 25 mg once daily eGFR < 15 mL/min/1.73 m^2 or\u00a0patient requiring dialysis- Use is not recommended"}
{"id": "article-38808_13", "title": "Mirabegron -- Administration -- Pregnancy Considerations", "content": "In preclinical studies, decreased fetal weight and increased fetal mortality were observed, and, in rabbits, fetal cardiomegaly was observed. No studies have been conducted regarding the use of mirabegron in pregnant patients to inform a drug-associated risk of miscarriages, significant congenital disabilities, or adverse maternal or fetal outcomes. Use with caution.", "contents": "Mirabegron -- Administration -- Pregnancy Considerations. In preclinical studies, decreased fetal weight and increased fetal mortality were observed, and, in rabbits, fetal cardiomegaly was observed. No studies have been conducted regarding the use of mirabegron in pregnant patients to inform a drug-associated risk of miscarriages, significant congenital disabilities, or adverse maternal or fetal outcomes. Use with caution."}
{"id": "article-38808_14", "title": "Mirabegron -- Administration -- Breastfeeding Considerations", "content": "There is a lack of safety data regarding using mirabegron during breastfeeding. Hypothetically, mirabegron has moderately high protein binding and relatively low bioavailability, so exposure to the breastfed infant is likely to be low. If the mother requires mirabegron, discontinuing breastfeeding is not a reason. Still, until more data become available, an alternate drug may be preferred while nursing a newborn or preterm infant. Hence, the risk-benefit analysis should be considered while prescribing mirabegron to nursing mothers. [11]", "contents": "Mirabegron -- Administration -- Breastfeeding Considerations. There is a lack of safety data regarding using mirabegron during breastfeeding. Hypothetically, mirabegron has moderately high protein binding and relatively low bioavailability, so exposure to the breastfed infant is likely to be low. If the mother requires mirabegron, discontinuing breastfeeding is not a reason. Still, until more data become available, an alternate drug may be preferred while nursing a newborn or preterm infant. Hence, the risk-benefit analysis should be considered while prescribing mirabegron to nursing mothers. [11]"}
{"id": "article-38808_15", "title": "Mirabegron -- Adverse Effects", "content": "Adverse drug reactions to mirabegron are generally mild and tolerable. One study showed that the adverse effects of mirabegron include hypertension (most commonly), nasopharyngitis, and urinary tract infection. [12] Dry mouth (a common side effect of anti-muscarinic) is six-fold less in mirabegron\u00a0because mirabegron does not affect the muscarinic receptors in the salivary glands. [12] Other side effects include tachycardia, headache, back pain, dizziness, palpitations, atrial fibrillation, urticarial reaction, joint pain, and swelling. [13]", "contents": "Mirabegron -- Adverse Effects. Adverse drug reactions to mirabegron are generally mild and tolerable. One study showed that the adverse effects of mirabegron include hypertension (most commonly), nasopharyngitis, and urinary tract infection. [12] Dry mouth (a common side effect of anti-muscarinic) is six-fold less in mirabegron\u00a0because mirabegron does not affect the muscarinic receptors in the salivary glands. [12] Other side effects include tachycardia, headache, back pain, dizziness, palpitations, atrial fibrillation, urticarial reaction, joint pain, and swelling. [13]"}
{"id": "article-38808_16", "title": "Mirabegron -- Adverse Effects", "content": "Mirabegron is generally considered a safe and effective drug. Mirabegron may also be more useful in the elderly population as the neurocognitive concerns of anti-muscarinic therapy may not be as much of a problem; however, this requires further investigation.\u00a0According to the manufacturer's labeling, cases of angioedema have been reported, which can be life-threatening and require immediate drug discontinuation and prompt treatment. Mirabegron can increase blood pressure significantly, and its use is not recommended for use in patients with uncontrolled hypertension. In three years of post-marketing surveillance study, an increase in residual urine volume and urinary retention was recognized as a serious adverse drug reaction related to mirabegron therapy. The risk of urinary retention increases in patients with significant bladder outlet obstruction\u00a0with simultaneous use of anti-muscarinic drugs to treat\u00a0an overactive bladder. Other common ADRs reported were constipation and dysuria. [14]", "contents": "Mirabegron -- Adverse Effects. Mirabegron is generally considered a safe and effective drug. Mirabegron may also be more useful in the elderly population as the neurocognitive concerns of anti-muscarinic therapy may not be as much of a problem; however, this requires further investigation.\u00a0According to the manufacturer's labeling, cases of angioedema have been reported, which can be life-threatening and require immediate drug discontinuation and prompt treatment. Mirabegron can increase blood pressure significantly, and its use is not recommended for use in patients with uncontrolled hypertension. In three years of post-marketing surveillance study, an increase in residual urine volume and urinary retention was recognized as a serious adverse drug reaction related to mirabegron therapy. The risk of urinary retention increases in patients with significant bladder outlet obstruction\u00a0with simultaneous use of anti-muscarinic drugs to treat\u00a0an overactive bladder. Other common ADRs reported were constipation and dysuria. [14]"}
{"id": "article-38808_17", "title": "Mirabegron -- Contraindications", "content": "Previous\u00a0hypersensitivity reaction to mirabegron or any\u00a0excipients of\u00a0tablet or oral suspension is a contraindication to mirabegron use.  Mirabegron use correlates with hypertension, and its contraindication includes severe uncontrolled hypertension. [15] Analysis of hypertension should depend on the discretion of the clinician. Resistant hypertension is defined as blood pressure that remains elevated above 140/90 despite using three antihypertensive drugs at the most tolerated doses, one of which is a diuretic.\u00a0In this light, blood pressure optimization should be considered before initiating mirabegron therapy. [16]", "contents": "Mirabegron -- Contraindications. Previous\u00a0hypersensitivity reaction to mirabegron or any\u00a0excipients of\u00a0tablet or oral suspension is a contraindication to mirabegron use.  Mirabegron use correlates with hypertension, and its contraindication includes severe uncontrolled hypertension. [15] Analysis of hypertension should depend on the discretion of the clinician. Resistant hypertension is defined as blood pressure that remains elevated above 140/90 despite using three antihypertensive drugs at the most tolerated doses, one of which is a diuretic.\u00a0In this light, blood pressure optimization should be considered before initiating mirabegron therapy. [16]"}
{"id": "article-38808_18", "title": "Mirabegron -- Monitoring", "content": "It is recommended to monitor blood pressure at baseline and during follow-up visits.\u00a0Monitor\u00a0quality of life based on the overactive bladder questionnaire (OAB-q) to assess the response to therapy. [17] Mirabegron is absorbed fairly quickly after oral administration, with maximum plasma concentration achieved in roughly 3 hours.", "contents": "Mirabegron -- Monitoring. It is recommended to monitor blood pressure at baseline and during follow-up visits.\u00a0Monitor\u00a0quality of life based on the overactive bladder questionnaire (OAB-q) to assess the response to therapy. [17] Mirabegron is absorbed fairly quickly after oral administration, with maximum plasma concentration achieved in roughly 3 hours."}
{"id": "article-38808_19", "title": "Mirabegron -- Monitoring", "content": "The liver\u2019s CYP450 system predominantly metabolizes mirabegron. Monitoring and dose adjustment should occur with patients on other medications with a narrow therapeutic index and also undergo metabolism via CYP2D6. [13] According to American Family Physicians (AAFP), potent inhibitors of the CYP2D6 system are amiodarone, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, and terbinafine. Substrates of the CYP2D6 system are amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, and tramadol. There are no significant inducers. In this light, it is vital to consider all comorbidities and drugs patients are on to prevent undesirable drug-drug interactions. It is recommended to take a thorough history, considering past medical history and review of medications before starting mirabegron therapy. [2]", "contents": "Mirabegron -- Monitoring. The liver\u2019s CYP450 system predominantly metabolizes mirabegron. Monitoring and dose adjustment should occur with patients on other medications with a narrow therapeutic index and also undergo metabolism via CYP2D6. [13] According to American Family Physicians (AAFP), potent inhibitors of the CYP2D6 system are amiodarone, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, and terbinafine. Substrates of the CYP2D6 system are amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, and tramadol. There are no significant inducers. In this light, it is vital to consider all comorbidities and drugs patients are on to prevent undesirable drug-drug interactions. It is recommended to take a thorough history, considering past medical history and review of medications before starting mirabegron therapy. [2]"}
{"id": "article-38808_20", "title": "Mirabegron -- Toxicity", "content": "Mirabegron has been shown to have a very broad safety level in humans. Caution is advisable with drugs that exert effects on or are metabolized by the liver, as mirabegron is also hepatically metabolized. Though safe in humans, studies have shown toxicity in dogs in the form of tachycardia and erythema. [18] Mirabegron is administered to healthy volunteers at up to 400 mg daily, and adverse drug reactions were palpitations and tachycardia. Multiple doses of high-dose mirabegron for ten days showed elevated blood pressure and pulse rate. In suspected overdosage cases, pulse rate, blood pressure, and EKG monitoring are suggested. There is no antidote for mirabegron overdose. Management of mirabegron overdosage is supportive. (This is according to the manufacturer's product labeling).", "contents": "Mirabegron -- Toxicity. Mirabegron has been shown to have a very broad safety level in humans. Caution is advisable with drugs that exert effects on or are metabolized by the liver, as mirabegron is also hepatically metabolized. Though safe in humans, studies have shown toxicity in dogs in the form of tachycardia and erythema. [18] Mirabegron is administered to healthy volunteers at up to 400 mg daily, and adverse drug reactions were palpitations and tachycardia. Multiple doses of high-dose mirabegron for ten days showed elevated blood pressure and pulse rate. In suspected overdosage cases, pulse rate, blood pressure, and EKG monitoring are suggested. There is no antidote for mirabegron overdose. Management of mirabegron overdosage is supportive. (This is according to the manufacturer's product labeling)."}
{"id": "article-38808_21", "title": "Mirabegron -- Enhancing Healthcare Team Outcomes", "content": "A study reviewed the interdisciplinary care of urinary incontinence between clinicians, nursing, physical therapy, and pharmacy. Advanced\u00a0Practice Registered Nurses and physical therapists\u00a0had\u00a0a significant role in Long-term Care Facilities. \u201cPrevention Focused Intervention: UI Based on the Health Promotion and Disease Prevention Model\u201d\u00a0 demonstrated\u00a0that interdisciplinary team approaches are crucial to achieving better patient outcomes, as demonstrated by\u00a0statistically significant reductions in urinary incontinence episodes. [19] According to American Urological Association (AUA) guidelines, clinicians should offer \u03b23-adrenoceptor agonists (mirabegron) as second-line therapy. [20] [2] [Level 1, Grade B]", "contents": "Mirabegron -- Enhancing Healthcare Team Outcomes. A study reviewed the interdisciplinary care of urinary incontinence between clinicians, nursing, physical therapy, and pharmacy. Advanced\u00a0Practice Registered Nurses and physical therapists\u00a0had\u00a0a significant role in Long-term Care Facilities. \u201cPrevention Focused Intervention: UI Based on the Health Promotion and Disease Prevention Model\u201d\u00a0 demonstrated\u00a0that interdisciplinary team approaches are crucial to achieving better patient outcomes, as demonstrated by\u00a0statistically significant reductions in urinary incontinence episodes. [19] According to American Urological Association (AUA) guidelines, clinicians should offer \u03b23-adrenoceptor agonists (mirabegron) as second-line therapy. [20] [2] [Level 1, Grade B]"}
{"id": "article-38808_22", "title": "Mirabegron -- Enhancing Healthcare Team Outcomes", "content": "According to one study, the rate of serious adverse effects of mirabegron was low and not directly related to the drug itself. [15] [Level 1a, Grade A]\u00a0Pooled safety data from SCORPIO, ARIES, and CAPRICORN (three large randomized, controlled clinical trials) have shown that there is no dose-response relationship among treatment groups for rates of treatment-emergent adverse effects (TEAE) with mirabegron. [21] Recommendations for managing patients on mirabegron include periodic measurement of blood pressure and symptomatic investigation of urinary retention tract infection; accomplishing this goal is best with an interprofessional healthcare team approach that includes prescribing clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists.\u00a0If there are any questions among interprofessional team members regarding the indications, dosing, or interactions of mirabegron, they should reach out to the pharmacist, who can perform medication reconciliation and report back to the prescriber or nurse. Open communication and collaborative efforts will result in improved patient outcomes with a lower incidence of adverse events when this interprofessional approach to care is in place. [Level 5]", "contents": "Mirabegron -- Enhancing Healthcare Team Outcomes. According to one study, the rate of serious adverse effects of mirabegron was low and not directly related to the drug itself. [15] [Level 1a, Grade A]\u00a0Pooled safety data from SCORPIO, ARIES, and CAPRICORN (three large randomized, controlled clinical trials) have shown that there is no dose-response relationship among treatment groups for rates of treatment-emergent adverse effects (TEAE) with mirabegron. [21] Recommendations for managing patients on mirabegron include periodic measurement of blood pressure and symptomatic investigation of urinary retention tract infection; accomplishing this goal is best with an interprofessional healthcare team approach that includes prescribing clinicians (MDs, DOs, NPs, PAs), nursing staff, and pharmacists.\u00a0If there are any questions among interprofessional team members regarding the indications, dosing, or interactions of mirabegron, they should reach out to the pharmacist, who can perform medication reconciliation and report back to the prescriber or nurse. Open communication and collaborative efforts will result in improved patient outcomes with a lower incidence of adverse events when this interprofessional approach to care is in place. [Level 5]"}
{"id": "article-38808_23", "title": "Mirabegron -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Mirabegron -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}